Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Mol Aspects Med. 2021 Aug 2;83:101007. doi: 10.1016/j.mam.2021.101007

Figure 3.

Figure 3.

PC7A polymer nanovaccines for anticancer therapy. A) Neoantigen peptides mixed with PC7A polymers self-assemble into nanovaccines. Once administered, the PC7A nanovaccine can deliver the peptides to the cytosol, and the polymers can directly activate STING to generate antigen-specific T cells. B) Treatment with a PC7A nanovaccine loaded with tumor associated antigens (TAAs) slows the growth B16F10 melanoma tumors. C) A neoantigen peptide-loaded PC7A nanovaccine effectively controls tumor growth in an MC38 colorectal cancer model. D) Combination of anti-PD-1 checkpoint blockade with an antigen peptide-loaded PC7A nanovaccine inhibits tumor growth in a TC-1 model. Reproduced with permission (Luo et al., 2017b). Copyright 2017, Springer Nature.